150mg Erlocip Erlotinib Tablet

150mg Erlocip Erlotinib Tablet Specification

Indication
Non-small cell lung cancer, Pancreatic cancer

Dosage Form
Tablet

Salt Composition
Erlotinib 150mg

Enzyme Types
Tyrosine kinase inhibitor (TKI)

Feature
Oral administration, prescription only

Ingredients
Erlotinib Hydrochloride, Excipients

Application
Oncology

Physical Color/Texture
White to off-white, round film-coated tablets

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits EGFR tyrosine kinase activity

Storage Instructions
Store below 30C, protect from moisture

Shelf Life
24 months

Warning
Should be taken under medical supervision

Product Registration
Certified as per local regulatory authorities

Brand Name
Erlocip

Prescription/Non Prescription
Prescription

Manufactured By
Cipla Ltd.

Packaging Size
1 x 30 tablets (commonly available)

ATC Code
L01EB02

Route of Administration
Oral

Strength
150 mg per tablet

150mg Erlocip Erlotinib Tablet Trade Information

Minimum Order Quantity
50 Packs

Supply Ability
1000 Packs Per Month

Delivery Time
7 Days

About 150mg Erlocip Erlotinib Tablet

Stay ahead in oncology care with Erlocip 150mg Erlotinib Tablets-one of the trending, highly recommended, and new release therapies for non-small cell lung cancer and pancreatic cancer. Manufactured by Cipla Ltd., Erlocip offers unprecedented efficacy through its classic action as a tyrosine kinase inhibitor, providing wondrous clinical benefits in targeted cancer treatment. Each box contains 30 white to off-white, round film-coated tablets designed for oral administration. Erlocip is certified by local regulatory authorities and should only be consumed with a valid prescription under strict medical supervision to ensure optimal safety and efficacy.

Diverse Application Areas & Commercial Utility

Erlocip 150mg Erlotinib Tablet finds wide application in advanced oncology, primarily targeting non-small cell lung cancer and pancreatic cancer. Its area of application spans specialized cancer treatment centers, multi-specialty hospitals, and leading clinical research facilities. Commercially, this medication is highly valued among exporters, suppliers, and traders across the Indian pharmaceutical market. The tablet's recognized efficacy and safety profile make it indispensable in modern cancer therapy regimes, supporting both routine clinical practice and innovative treatment approaches.

Packaging Details, Market Reach & Timely Delivery

Packaged securely as 1 x 30 tablets for maximum preservation, Erlocip 150mg ensures the shipped goods reach customers in optimal condition. Transport services are managed efficiently to maintain market value throughout the supply chain. The main domestic market for Erlocip spans across India's key medical hubs, with steady demand from pharmacies and hospitals. Delivery times are carefully monitored, typically ensuring availability within a few days from order, supported by reliable logistics and inventory management systems.

FAQ's of 150mg Erlocip Erlotinib Tablet:

Q: How should Erlocip 150mg Erlotinib Tablets be administered?

A: Erlocip 150mg is intended for oral administration and should always be taken exactly as prescribed by a healthcare professional, ideally at the same time each day, either at least one hour before or two hours after food.

Q: What cancers are primarily treated with Erlocip Erlotinib 150mg?

A: Erlocip is mainly used in the management of non-small cell lung cancer and pancreatic cancer, working as a targeted therapy to inhibit EGFR tyrosine kinase activity.

Q: When is Erlocip 150mg Erlotinib typically prescribed during cancer treatment?

A: This medication is commonly prescribed in advanced cancer stages, particularly when tumors have specific molecular characteristics suitable for tyrosine kinase inhibitor therapy, or after other standard treatments have been considered.

Q: Where can Erlocip 150mg Tablets be purchased?

A: Erlocip 150mg is available through authorized pharmacies, hospitals, and registered exporters or suppliers in India, but can only be dispensed with a valid doctor's prescription.

Q: What is the benefit of using Erlocip over traditional chemotherapy?

A: Erlocip targets specific cancer cell mechanisms as a tyrosine kinase inhibitor, which allows for more precise therapy with a different side effect profile compared to traditional chemotherapy, potentially improving patient outcomes in indicated cases.

Tell us about your requirement